Immediate Impact
8 standout
Citing Papers
Regulatory mechanisms of PD-1/PD-L1 in cancers
2024 Standout
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
2024 Standout
Works of Michaela Barbier being referenced
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
2021
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Michaela Barbier | 92 | 53 | 45 | 148 | 63 | 13 | 280 | |
| Ji-Hung Wang | 33 | 34 | 18 | 180 | 42 | 14 | 317 | |
| Jeremy Man Ho Hui | 66 | 27 | 28 | 119 | 92 | 23 | 246 | |
| Irene Hsu | 94 | 121 | 8 | 106 | 25 | 19 | 318 | |
| Munenori Kosugi | 27 | 85 | 25 | 128 | 25 | 10 | 316 | |
| Jack Ishak | 46 | 55 | 143 | 63 | 35 | 19 | 332 | |
| Keiichi Kohashi | 29 | 76 | 24 | 115 | 24 | 13 | 297 | |
| Yinghong Zhai | 46 | 27 | 122 | 48 | 27 | 20 | 315 | |
| Amanda Dudley | 52 | 40 | 23 | 125 | 60 | 9 | 290 | |
| Masafumi Tatsukawa | 71 | 131 | 9 | 122 | 64 | 13 | 329 | |
| Sara Lightowlers | 16 | 49 | 30 | 114 | 42 | 16 | 223 |
All Works
Login with ORCID to disown or claim papers
Loading papers...